REDVAULT BIOSCIENCES LP
Houston, TX · Biotech · Private
Long template dumbbell (LTD) NGS library preparation technology for long-read genome sequencing and de novo assembly
- Grants
- $1.4M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 7
- 2 granted · 5 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20152017201920212023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Efficient Creation of Long-Template Libraries for Next-Generation Sequencing | $146,801 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Digital Analysis of Plasma miRNA populations in Pancreatic Cancer | $249,829 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Digital Analysis of Plasma miRNA populations in Pancreatic Cancer | $149,859 | |
| Federal grant | Department of Health and Human Services · Phase I · Digital Analysis of Plasma miRNA populations in Pancreatic Cancer | $49,970 | |
| Federal grant | Department of Health and Human Services · Phase I · Digital Analysis of Plasma miRNA populations in Pancreatic Cancer | $50,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Solid-phase replication of long template libraries for NGS applications | $223,895 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Solid-phase replication of long template libraries for NGS applications | $223,895 | |
| Federal grant | Department of Health and Human Services · Phase I · PA21-259, SBIR, Phase I, POC detection of chlamydia and gonorrhea small RNAs using a target reporter construct assay by lateral flow in urine surrogates | $299,928 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2868 | BETASTEM THERAPUETICS, INC. | — | — |
| 2869 | NUTRIWYO, LLC | — | — |
| 2870 | Nutcracker Therapeutics | — | $172M |
| 2871 | REDVAULT BIOSCIENCES LP | — | — |
| 2872 | Vertex Pharmaceuticals | — | — |
| 2873 | Q-State Biosciences, Inc. | — | — |
| 2874 | NEUCORE BIO, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Target Reporter Constructs And Uses Thereofgranted
- Systems And Methods For Clonal Replication And Amplification Of Nucleic Acid Molecules For Genomic And Therapeutic Applicationsapplication
- Target Reporter Constructs And Uses Thereofgranted
- Systems And Methods For Clonal Replication And Amplification Of Nucleic Acid Molecules For Genomic And Therapeutic Applicationsapplication
- Target Reporter Constructs And Uses Thereofapplication
- Target Reporter Circles And Uses Thereofapplication
- Systems And Methods For Clonal Replication And Amplification Of Nucleic Acid Molecules For Genomic And Therapeutic Applicationsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.